Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H1 2016

Publication ID: GMD0516173
Publication Date: May 31, 2016
Pages: 72
Publisher: Global Markets Direct
Countries: Global [1]

$2,000.00

Publication License Type *

- SINGLE USER LICENSE (PDF), $2,000.00
- SITE LICENSE (PDF), $4,000.00
- GLOBAL LICENSE (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Summary

Global Markets Direct’s, ‘Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H1 2016’, provides an overview of the Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
- The report reviews pipeline therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) therapeutics and enlists all their major and minor projects
- The report assesses Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents:

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Overview 7
Therapeutics Development 8
Pipeline Products for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Overview 8
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics under Development by Companies 9
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Products under Development by Companies 13
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Companies Involved in Therapeutics Development 14
Biscayne Pharmaceuticals, Inc. 14
GW Pharmaceuticals Plc 15
INSYS Therapeutics, Inc. 16
OPKO Health, Inc. 17
PTC Therapeutics, Inc. 18
Sage Therapeutics, Inc. 19
Xenon Pharmaceuticals Inc. 20
Zogenix, Inc. 21
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
ataluren - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BIS-001 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
cannabidiol - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
cannabidiol - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CUR-1916 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
fenfluramine hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Oligonucleotide for Dravet Syndrome - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
SAGE-217 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Recent Pipeline Updates 46
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects 60
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Product Development Milestones 61
Featured News & Press Releases 61
May 05, 2016: Zogenix Announces ZX008 New Efficacy and Safety Data for Treatment of Seizures in Dravet Syndrome 61
Apr 21, 2016: New Data on Zogenix ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress 62
Mar 14, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol) 62
Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals 64
Jan 19, 2016: Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome 64
Jan 11, 2016: Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome 64
Dec 14, 2015: Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome 65
Dec 07, 2015: Biscayne Pharmaceuticals Presents Data At 2015 AES Meeting Confirming BIS-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug 65
Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy 66
Dec 07, 2015: Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome 69
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72

List of Tables
Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016 14
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by GW Pharmaceuticals Plc, H1 2016 15
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by INSYS Therapeutics, Inc., H1 2016 16
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by OPKO Health, Inc., H1 2016 17
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by PTC Therapeutics, Inc., H1
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Sage Therapeutics, Inc., H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Xenon Pharmaceuticals Inc., H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Zogenix, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics - Recent Pipeline Updates, H1 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016

Companies Mentioned:

Biscayne Pharmaceuticals, Inc.
GW Pharmaceuticals Plc
INSYS Therapeutics, Inc.
OPKO Health, Inc.
PTC Therapeutics, Inc.
Sage Therapeutics, Inc.
Xenon Pharmaceuticals Inc.
Zogenix, Inc.

License Types:

**Single User License (PDF)**
- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Site License (PDF)**
- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Global License (PDF)**
- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.*